Is PRLD or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Maplight Therapeutics N/A N/A N/A

Is PRLD or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Aktis Oncology N/A N/A N/A

Is PRLD or KALV more profitable?

Prelude Therapeutics' return on equity of -118.24% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% KalVista Pharmaceuticals N/A -341.44% -111.94%

Prelude Therapeutics (PRLD) Competitors

$4.46 +0.02 (+0.50%)

As of 12:35 PM Eastern

Compare

PRLD vs. MPLT, XERS, AKTS, MRVI, and KALV

Should you buy Prelude Therapeutics stock or one of its competitors? MarketBeat compares Prelude Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prelude Therapeutics include Maplight Therapeutics (MPLT), Xeris Biopharma (XERS), Aktis Oncology (AKTS), Maravai LifeSciences (MRVI), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Prelude Therapeutics compare to Maplight Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Prelude Therapeutics has higher revenue and earnings than Maplight Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.36	-$99.50M	-$1.00	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

79.7% of Prelude Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Maplight Therapeutics	N/A	N/A	N/A

Prelude Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 71.28%. Maplight Therapeutics has a consensus price target of $39.10, indicating a potential upside of 5.80%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

In the previous week, Maplight Therapeutics had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 0.70 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Very Positive
Maplight Therapeutics	Positive

Summary

Prelude Therapeutics and Maplight Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to Xeris Biopharma?

Prelude Therapeutics (NASDAQ:PRLD) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Prelude Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 71.28%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 30.83%. Given Prelude Therapeutics' higher probable upside, equities research analysts plainly believe Prelude Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Prelude Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Xeris Biopharma	3.81%	735.00%	3.24%

Xeris Biopharma has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.36	-$99.50M	-$1.00	N/A
Xeris Biopharma	$291.85M	4.88	$550K	$0.06	137.58

Prelude Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Xeris Biopharma had 5 more articles in the media than Prelude Therapeutics. MarketBeat recorded 6 mentions for Xeris Biopharma and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat Xeris Biopharma's score of 0.19 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Very Positive
Xeris Biopharma	Neutral

Summary

Xeris Biopharma beats Prelude Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Prelude Therapeutics compare to Aktis Oncology?

Prelude Therapeutics (NASDAQ:PRLD) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Aktis Oncology had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat Aktis Oncology's score of 1.07 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Very Positive
Aktis Oncology	Positive

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aktis Oncology has lower revenue, but higher earnings than Prelude Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.36	-$99.50M	-$1.00	N/A
Aktis Oncology	$6.50M	215.24	-$63.73M	-$0.38	N/A

Prelude Therapeutics presently has a consensus price target of $7.67, indicating a potential upside of 71.28%. Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 32.06%. Given Prelude Therapeutics' higher probable upside, equities research analysts clearly believe Prelude Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aktis Oncology's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Prelude Therapeutics compare to Maravai LifeSciences?

Prelude Therapeutics (NASDAQ:PRLD) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Prelude Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 equaled Maravai LifeSciences'average media sentiment score.

Company	Overall Sentiment
Prelude Therapeutics	Very Positive
Maravai LifeSciences	Very Positive

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prelude Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 71.28%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential downside of 14.93%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Prelude Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Prelude Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Prelude Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.36	-$99.50M	-$1.00	N/A
Maravai LifeSciences	$185.74M	8.99	-$130.77M	-$0.71	N/A

Summary

Prelude Therapeutics beats Maravai LifeSciences on 9 of the 14 factors compared between the two stocks.

How does Prelude Therapeutics compare to KalVista Pharmaceuticals?

Prelude Therapeutics (NASDAQ:PRLD) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Prelude Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Prelude Therapeutics' return on equity of -118.24% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Prelude Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.36	-$99.50M	-$1.00	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Prelude Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 71.28%. KalVista Pharmaceuticals has a consensus target price of $33.25, suggesting a potential upside of 23.15%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

79.7% of Prelude Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 2 mentions for KalVista Pharmaceuticals and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.87 beat KalVista Pharmaceuticals' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Prelude Therapeutics	Very Positive
KalVista Pharmaceuticals	Neutral

Summary

Prelude Therapeutics beats KalVista Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Get Prelude Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRLD vs. The Competition

Export

Metric	Prelude Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$357.19M	$2.99B	$6.74B	$12.51B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-4.49	18.66	26.90	24.39
Price / Sales	29.36	822.95	587.69	117.46
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	4.11	4.22	10.92	6.33
Net Income	-$99.50M	$64.26M	$3.58B	$330.66M
7 Day Performance	-9.94%	-3.42%	-2.25%	-0.84%
1 Month Performance	-0.31%	2.26%	3.08%	-0.26%
1 Year Performance	445.85%	20.47%	26.23%	19.99%

Prelude Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRLD Prelude Therapeutics	3.8289 of 5 stars	$4.46 +0.5%	$7.67 +71.8%	+445.0%	$356.39M	$12.14M	N/A	120	Positive News
MPLT Maplight Therapeutics	1.6741 of 5 stars	$36.57 +4.4%	$38.80 +6.1%	N/A	$1.56B	N/A	N/A	109
XERS Xeris Biopharma	3.4166 of 5 stars	$8.93 +6.6%	$10.80 +21.0%	+59.7%	$1.55B	$291.85M	149.75	290
AKTS Aktis Oncology	2.5243 of 5 stars	$28.47 +7.2%	$34.00 +19.4%	N/A	$1.53B	$6.50M	N/A	76	News Coverage Positive News Analyst Forecast
MRVI Maravai LifeSciences	1.9237 of 5 stars	$5.83 -1.2%	$5.50 -5.6%	+133.0%	$1.51B	$185.74M	N/A	610	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRLD) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MPLT, XERS, AKTS, MRVI, and KALV

How does Prelude Therapeutics compare to Maplight Therapeutics?

Summary

How does Prelude Therapeutics compare to Xeris Biopharma?

Summary

How does Prelude Therapeutics compare to Aktis Oncology?

Summary

How does Prelude Therapeutics compare to Maravai LifeSciences?

Summary

How does Prelude Therapeutics compare to KalVista Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prelude Therapeutics (PRLD) Competitors

PRLD vs. MPLT, XERS, AKTS, MRVI, and KALV

How does Prelude Therapeutics compare to Maplight Therapeutics?

Which has higher earnings & valuation, PRLD or MPLT?

Do insiders & institutionals believe in PRLD or MPLT?

Is PRLD or MPLT more profitable?

Do analysts prefer PRLD or MPLT?

Does the media prefer PRLD or MPLT?

Summary

How does Prelude Therapeutics compare to Xeris Biopharma?

Do analysts rate PRLD or XERS?

Is PRLD or XERS more profitable?

Which has stronger earnings and valuation, PRLD or XERS?

Which has more risk and volatility, PRLD or XERS?

Do insiders and institutionals have more ownership in PRLD or XERS?

Does the media prefer PRLD or XERS?

Summary

How does Prelude Therapeutics compare to Aktis Oncology?

Does the media prefer PRLD or AKTS?

Do insiders and institutionals hold more shares of PRLD or AKTS?

Which has higher valuation and earnings, PRLD or AKTS?

Do analysts rate PRLD or AKTS?

Is PRLD or AKTS more profitable?

Summary

How does Prelude Therapeutics compare to Maravai LifeSciences?

Which has more volatility and risk, PRLD or MRVI?

Does the media favor PRLD or MRVI?

Do institutionals & insiders have more ownership in PRLD or MRVI?

Do analysts recommend PRLD or MRVI?

Is PRLD or MRVI more profitable?

Which has higher valuation and earnings, PRLD or MRVI?

Summary

How does Prelude Therapeutics compare to KalVista Pharmaceuticals?

Which has more volatility and risk, PRLD or KALV?

Is PRLD or KALV more profitable?

Which has better earnings and valuation, PRLD or KALV?

Do analysts recommend PRLD or KALV?

Do institutionals and insiders hold more shares of PRLD or KALV?

Does the media prefer PRLD or KALV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD vs. The Competition

Prelude Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools